Close menu




September 17th, 2025 | 07:00 CEST

Tokenization as an efficiency booster: Finexity, London Stock Exchange, eToro

  • Tokenization
  • crypto
  • Investments
  • Trading
Photo credits: pixabay.com

Digitalization has fundamentally changed the way we invest. What began decades ago with the rise of online brokers is now continuing with tokenized assets and the use of AI. As the CFA Institute writes, the use of blockchain technology means faster transactions, less settlement friction, and ultimately lower costs. Innovative companies around the world are setting out to offer these advantages to better serve their customers, which is also good news for investors. We take a closer look at the business models of Finexity, the London Stock Exchange, and eToro in the field of tokenization.

time to read: 3 minutes | Author: Nico Popp
ISIN: FINEXITY AG | DE000A40ET88 , LONDON STOCK EXCHANGE | GB00B0SWJX34 , ETORO GROUP LTD | VGG320891077

Table of contents:


    Finexity: Growth with private markets

    The Hamburg-based company Finexity operates a digital exchange for tokenized private markets such as private credit, real estate, infrastructure, renewable energy, and art collections. The platform connects issuers of digital securities with regulated trading partners, including savings banks, credit unions, and asset managers, and currently has more than 84,000 registered investors. Finexity covers the entire value chain, from economic consulting and structuring to tokenization, subscription, OTC trading, and securities settlement. To date, the platform has listed around 250 securities from 50 issuers.

    In the coming quarters, Finexity's exchange is set to become a fully regulated multilateral trading facility (MTF). The Company plans to submit the relevant applications before the end of this year. At the same time, the Company is planning further acquisitions following its recent purchase of 90.1% of the shares in Effecta GmbH, its liability umbrella company. Potential targets are primarily intended to advance Finexity technologically and complement the business model of the Company, which is considered one of the German pioneers in the field of tokenization. The fact that Finexity has been listed on the stock exchange itself since this month is convenient – its own shares could be used as takeover currency in the future. The private markets sector, in which Finexity operates, has so far been reserved primarily for professional investors and promises significant growth. Finexity AG's stock market debut has been successful so far. Unlike many comparable IPOs, there is no selling pressure from existing shareholders at Finexity.

    London Stock Exchange: Tokenized issuances as a growth driver

    Innovative technology is also playing a growing role at the London Stock Exchange (LSE). The Group includes the London and Milan stock exchanges, several clearing houses, the index providers FTSE Russell, and various financial information providers. Just recently, the LSE launched the Digital Markets Infrastructure (DMI) project in collaboration with Microsoft Azure. The DMI platform enables the tokenized issuance and management of private funds using blockchain technology, aiming to achieve economies of scale and efficiency across the entire asset lifecycle. The exchange operator emphasizes its desire to be a global leader in the development of digital asset ecosystems. For management, the digitization of financial markets is one of the key trends for the future.

    eToro: A challenge to stock exchange operators

    The eToro trading platform has also proven to be innovative in the past and is considered one of the pioneers in the field of social trading. Up to 40 million users can trade stocks, ETFs, cryptocurrencies, foreign exchange, and CFDs or copy other investors' portfolios. eToro also sees great opportunities in the area of tokenization. CEO Yoni Assia repeatedly emphasizes that blockchain technology will lead to the largest transfer of wealth in history by tokenizing traditional assets. In July, eToro announced that it would offer selected US stocks in tokenized form and allow them to be traded around the clock. This is a challenge to operators of traditional exchanges, which are bound by specific trading hours.

    Finexity: Well-positioned for the future

    When you consider that tokenized securities promise significant efficiency gains with every transaction, it stands to reason that more and more traditional assets will gradually be transferred to the blockchain. While the pressure to act does not yet seem so great for traditional stocks—after all, the fees are already manageable today—the potential for real assets or other private markets is significantly greater. Here, tokenization also ensures that these asset classes are first discovered by private investors. The Hamburg-based company Finexity is ideally positioned to benefit from this development. With active involvement in regulatory developments over recent years, the Company has laid a strong foundation for targeted acquisitions and an integrated service offering. The Finexity share, which is listed on the Munich Stock Exchange, is worth a closer look.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read